FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2904683944> ?p ?o ?g. }

• W2904683944 endingPage "1414" @default.
• W2904683944 startingPage "1409" @default.
• W2904683944 abstract "Background The combination of mitotane and platinum-etoposide chemotherapy is a front-line treatment in metastatic adrenocortical carcinoma (ACC), although this regimen shows limited efficacy. Pharmacokinetic drug-drug interaction between mitotane, a strong CYP3A4 inducer, and etoposide, which is a substrate of CYP3A4, may contribute to chemoresistance. The aim of this pilot study was to assess the pharmacokinetic interaction between mitotane and etoposide in ACC patients. Methods Five consecutive ACC patients treated with platinum etoposide (120-150 mg/m2 day 1-2-3 at cycle 1), with or without concomitant mitotane, were included. In the absence of limiting toxicity, a dose escalation of etoposide was proposed since cycle 2. Plasma etoposide concentrations were measured using liquid chromatography at 0, 4 and 24 h after each infusion. Clearance and area under the curve (AUC) of etoposide were determined at each cycle. Results Patients received two to six chemotherapy cycles, in association with mitotane (N = 4) or after mitotane discontinuation (N = 1). Etoposide clearance was two-fold higher with concomitant mitotane (4.95 L/h) than after mitotane discontinuation (2.53 L/h, P = 0.014), and 2.5-fold higher than that in reference population not treated with mitotane (1.81 L/h). Etoposide dose escalation was performed in four patients under mitotane, resulting in two minor tumor responses and one severe toxicity (febrile aplasia) at dose of 300 mg/m2/day. Tumor response was associated with higher etoposide AUC (267.3 vs 188.8 mg.h/L, P = 0.04). Conclusion A drug-drug interaction between mitotane and etoposide may contribute to the low efficacy of platinum-etoposide chemotherapy. This pilot study suggests further a potential benefit of increasing etoposide dose in ACC patients receiving mitotane." @default.
• W2904683944 created "2018-12-22" @default.
• W2904683944 creator A5002862341 @default.
• W2904683944 creator A5008529320 @default.
• W2904683944 creator A5015222370 @default.
• W2904683944 creator A5020169596 @default.
• W2904683944 creator A5021402469 @default.
• W2904683944 creator A5022769149 @default.
• W2904683944 creator A5043315417 @default.
• W2904683944 creator A5065121477 @default.
• W2904683944 creator A5090828621 @default.
• W2904683944 date "2018-12-01" @default.
• W2904683944 modified "2023-10-18" @default.
• W2904683944 title "Pharmacokinetic interaction between mitotane and etoposide in adrenal carcinoma: a pilot study" @default.
• W2904683944 cites W1606582049 @default.
• W2904683944 cites W1967352082 @default.
• W2904683944 cites W1972162697 @default.
• W2904683944 cites W2011628325 @default.
• W2904683944 cites W2019370951 @default.
• W2904683944 cites W2020451259 @default.
• W2904683944 cites W2040745022 @default.
• W2904683944 cites W2052930651 @default.
• W2904683944 cites W2054216493 @default.
• W2904683944 cites W2069547611 @default.
• W2904683944 cites W2069819692 @default.
• W2904683944 cites W2072709644 @default.
• W2904683944 cites W2119534425 @default.
• W2904683944 cites W2130421223 @default.
• W2904683944 cites W2135121954 @default.
• W2904683944 cites W2142711036 @default.
• W2904683944 cites W2149227434 @default.
• W2904683944 cites W2153050324 @default.
• W2904683944 cites W2160063358 @default.
• W2904683944 cites W2330085861 @default.
• W2904683944 cites W2789028915 @default.
• W2904683944 cites W2796552195 @default.
• W2904683944 cites W99169869 @default.
• W2904683944 doi "https://doi.org/10.1530/ec-18-0428" @default.
• W2904683944 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6301193" @default.
• W2904683944 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30533000" @default.
• W2904683944 hasPublicationYear "2018" @default.
• W2904683944 type Work @default.
• W2904683944 sameAs 2904683944 @default.
• W2904683944 citedByCount "5" @default.
• W2904683944 countsByYear W29046839442019 @default.
• W2904683944 countsByYear W29046839442021 @default.
• W2904683944 countsByYear W29046839442022 @default.
• W2904683944 countsByYear W29046839442023 @default.
• W2904683944 crossrefType "journal-article" @default.
• W2904683944 hasAuthorship W2904683944A5002862341 @default.
• W2904683944 hasAuthorship W2904683944A5008529320 @default.
• W2904683944 hasAuthorship W2904683944A5015222370 @default.
• W2904683944 hasAuthorship W2904683944A5020169596 @default.
• W2904683944 hasAuthorship W2904683944A5021402469 @default.
• W2904683944 hasAuthorship W2904683944A5022769149 @default.
• W2904683944 hasAuthorship W2904683944A5043315417 @default.
• W2904683944 hasAuthorship W2904683944A5065121477 @default.
• W2904683944 hasAuthorship W2904683944A5090828621 @default.
• W2904683944 hasBestOaLocation W29046839441 @default.
• W2904683944 hasConcept C109650736 @default.
• W2904683944 hasConcept C112705442 @default.
• W2904683944 hasConcept C126322002 @default.
• W2904683944 hasConcept C126894567 @default.
• W2904683944 hasConcept C143998085 @default.
• W2904683944 hasConcept C2776694085 @default.
• W2904683944 hasConcept C2776735609 @default.
• W2904683944 hasConcept C2778119113 @default.
• W2904683944 hasConcept C2778715236 @default.
• W2904683944 hasConcept C2779384505 @default.
• W2904683944 hasConcept C2781399356 @default.
• W2904683944 hasConcept C29730261 @default.
• W2904683944 hasConcept C526171541 @default.
• W2904683944 hasConcept C62231903 @default.
• W2904683944 hasConcept C71924100 @default.
• W2904683944 hasConcept C90924648 @default.
• W2904683944 hasConcept C97320921 @default.
• W2904683944 hasConcept C98274493 @default.
• W2904683944 hasConceptScore W2904683944C109650736 @default.
• W2904683944 hasConceptScore W2904683944C112705442 @default.
• W2904683944 hasConceptScore W2904683944C126322002 @default.
• W2904683944 hasConceptScore W2904683944C126894567 @default.
• W2904683944 hasConceptScore W2904683944C143998085 @default.
• W2904683944 hasConceptScore W2904683944C2776694085 @default.
• W2904683944 hasConceptScore W2904683944C2776735609 @default.
• W2904683944 hasConceptScore W2904683944C2778119113 @default.
• W2904683944 hasConceptScore W2904683944C2778715236 @default.
• W2904683944 hasConceptScore W2904683944C2779384505 @default.
• W2904683944 hasConceptScore W2904683944C2781399356 @default.
• W2904683944 hasConceptScore W2904683944C29730261 @default.
• W2904683944 hasConceptScore W2904683944C526171541 @default.
• W2904683944 hasConceptScore W2904683944C62231903 @default.
• W2904683944 hasConceptScore W2904683944C71924100 @default.
• W2904683944 hasConceptScore W2904683944C90924648 @default.
• W2904683944 hasConceptScore W2904683944C97320921 @default.
• W2904683944 hasConceptScore W2904683944C98274493 @default.
• W2904683944 hasIssue "12" @default.
• W2904683944 hasLocation W29046839441 @default.
• W2904683944 hasLocation W29046839442 @default.

• next